IROS and partners use Emirati Genome Programme to identify high-risk individuals before symptoms appear
News
Viridian wins FDA approval for Lumvoa for thyroid eye disease
Company secures first commercial product with data for active and chronic TED
Racura treats first patient in phase 1 HARNESS‑1 lung cancer trial
No adverse events observed as study begins in EGFR‑mutant NSCLC
NICE recommends MSD’s pembrolizumab for locally advanced cervical cancer
First immunotherapy approved for LACC in England offers new treatment option for women
Lundbeck to present new Vyepti and bocunebart data at EAN 2026
Lundbeck will present new migraine data at the European Academy of Neurology Congress 2026, taking place from 27–30...
Agomab outlines design of phase 2b NOV‑ERA study in fibrostenosing Crohn’s disease
FDA alignment secured as company prepares to begin dosing in 2026
Pierre Fabre wins EC approval for Braftovi regimen in BRAFV600E‑mutant mCRC
Breakwater phase 3 data show significant gains in progression‑free survival
Cenrifki approved in EU for secondary progressive multiple sclerosis
Sanofi therapy becomes first disability‑targeting medicine for nrSPMS
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
Final draft guidance recommends D‑VRd on the NHS in England and Wales
Anocca doses first patients with precision TCR‑T therapy
Company begins phase 1 treatment in multi‑centre VIDAR‑1 trial
Connecta launches phase 2a trial of neuroplasticity modulator
Study marks major milestone for CTH120 as company advances disease‑modifying ambitions
Aquipta recommended by NICE for acute migraine treatment
Guidance paves the way for NHS access for eligible adults in England and Wales
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
SMC backs first GPRC5D‑targeting bispecific for patients after three or more treatments
Alzecure enters collaboration and with Lilly for Alzheimer’s project
Partnership grants Lilly global rights to Alzstatin ACD680
Survodutide trial data show targeted visceral and liver fat reductions
Phase 3 results highlight metabolic benefits alongside weight loss
